Dublin, July 10, 2018 (GLOBE NEWSWIRE) -- The "Automated and Rapid Microbiological Tests - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2015 through 2022. Also, a six-year historic analysis is provided for these markets. This report analyzes the worldwide markets in US$ Thousand by the following End-Use Segments:

  • Clinical Applications (Automated Identification & Susceptibility Systems, Automated Blood Culture Systems, Automated Tuberculosis Systems, Streptococcal Infection Rapid Tests, GC/Chlamydia Rapid Tests, & Other Automated & Rapid Microbiological Tests)
  • Non-Clinical Applications

The report profiles 83 companies including many key and niche players such as:

  • Abbott Laboratories (US)
  • Abbott Molecular, Inc. (US)
  • Alere Inc. (US)
  • Beckman Coulter, Inc. (US)
  • Becton Dickinson and Company (US)
  • bioMerieux SA (France)
  • bioMerieux, Inc. (US)
  • Bio-Rad Laboratories, Inc (US)
  • Cellabs Pty Ltd (Australia)
  • Cepheid Inc. (US)
  • CorisBioconcept SPRL (Belgium)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Hologic, Inc. (US)
  • MedMira Inc. (Canada)
  • Meridian Bioscience, Inc. (US)
  • OraSure Technologies, Inc. (US)
  • Orion Diagnostica Oy (Finland)
  • QIAGEN N.V. (The Netherlands)
  • Quidel Corporation (US)
  • Sekisui Diagnostics, LLC (US)
  • Siemens Healthcare GmbH (Germany)
  • Thermo Fisher Scientific Inc. (US)
  • Oxoid Limited (UK)

Key Topics Covered

1. INDUSTRY OVERVIEW Global In-Vitro Diagnostics Market Central Laboratories Dominate the Market Immunochemistry the Leading Segment Automated and Rapid Microbiological Tests Revolutionize Microbiological Testing Evolutionary Battle against Microbes Drives Market Future Automated Microbiological Tests: A Pesky Gray Area in the Clinical Diagnostics Market Instant Detection of Pathogens A New Epoch in the Fight for Survival Traditional Rapid Microbiological Tests Make Way for New, Probe Tests Emerging Markets Provide Tremendous Growth Opportunities Clinical Applications Non-Clinical Applications A Holistic Peek into a Few Noteworthy Trends The Evolution of Biotechnology A Crucial Step Ahead in the Growing Popularity of Rapid Microbial Tests Point-of-Care Rapid Microbiological Testing: Yet to Realize Its Full Potential 2. COMPETITION Competitive Dynamics in the C. Difficile Testing Market List of Select Molecular C. difficile Test Products 3. MARKET DRIVERS AND TRENDS Increasing Incidence of Infectious Diseases An Opportunity Indicator Rising Healthcare Needs of Aging Global Population A Growth Driver The World is Ageing Rising HIV Prevalence A Key Opportunity Indicator Some Significant HIV Statistics by Region: 2015 Rapid HIV Tests: A New Age Diagnostic Weapon against the Killer Disease Ultra-Rapid HIV-Screening Tests put up a Strong Fight against HIV-Epidemic Accuracy/Reliability of Home HIV Testing: A Bone of Contention Increase in Healthcare Spending in Emerging Markets to Propel Demand Rising Emphasis on Lab Automation to Augur Well for Market Growth Greater Patient Awareness to Drive Growth Advancements in Molecular Diagnostics A Boon Antibiotic Resistant Bacteria Throws the Spotlight on Microbial Testing Influenza Boosting Rapid Test Prospects Select FDA-approved Rapid Detection Tests for Flu A&B: (2015) Automated Blood Culture Systems: The Gold Standard in the Fight against Bacteremia Impact of Food Scares on Rapid Microbiological Tests Market Stringent Norms Necessitate Microbial Food Safety Testing Rapid Screening Gains Preference over Traditional Food Testing Procedures Conventional Testing Continues to Dominate but Rapid Tests Making Inroads Leading Food Processors Resort to Rapid Microbiological Testing Food Packages of the Future Ingrained with Microbial Alert Systems Poultry Industry Embraces Rapid Microbiological Testing Technologies Rapid Microbiological Tests Gain Significance in the Pharma Industry Key Advantages of Rapid Microbiological Tests for Pharma- In a Nutshell Growth Direct System Creates Waves in Pharmaceutical Quality Control 4. KEY ISSUES CONFRONTING THE RAPID MICROBIOLOGICAL TESTS MARKET Validation: An Imperative Prerequisite Obtaining Regulatory Approval: A Major Non-Technical Hindrance Non-Conformance to Testing Requirements: A Weighty Concern Technical and Cost Issues Impede the Uptake of Rapid Microbiological Tests in the Food Sector 5. PRODUCT/TECHNOLOGY OVERVIEW 6. APPLICATION AREAS OF AUTOMATED AND RAPID MICROBIOLOGICAL TESTS - A REVIEW Clinical Applications Automated Identification and Susceptibility Systems Automated Blood Culture Systems Automated Tuberculosis Systems Streptococcus Infection Rapid Tests GC/Chlamydia Rapid Tests Other Automated & Rapid Microbiological Tests Applications in Non-Clinical Investigations Food/Water Safety Tests Rapid Microbiological Methods in Pharmaceutical Sector Environmental Tests Other Miscellaneous Applications 7. PRODUCT INNOVATIONS/INTRODUCTIONS bioMrieux Launches New Platform for Extraction of DNA and RNA Bio-Rad Launches IH-1000 Blood Typing System bioMrieux Launches "EviSight Compact" Incubator System BD Launches Next Generation Automated ID/AST System Sekisui Introduces SEKURE TPLA and RPR Assays for Syphilis Testing BD Introduces BD Veritor Plus System Rhoenix Introduces Beer SpoilerAlert Assay Philips Introduces Minicare System Bio-Rad Introduces Amplichek II Quality Control Bruker Launches Enhancements for MALDI Biotyper Thermo Fisher Launches Thermo Scientific SureTect Cronobacter Species Real-Time PCR Assay Hologic Introduces Aptima Mycoplasma Genitalium Assay bioMrieux and Illumina Introduce bioMrieux EpiSeq bioMrieux Launches GENE-UP BioControl Launches Modular Automation for Assurance GDS Rapid Micro Biosystems Launches Growth Direct System IDEXX Launches Quanti-Tray Sealer PLUS in Europe Sekisui Introduces 3 New Assays to the OSOM Rapid Test Line Bio-Rad Launches IH-500 bioMrieux Launches VIDAS Lyme IgG II and VIDAS Lyme IgM II Assays in the US Meridian Introduces illumigene HSV Assays in Europe Medicinal Genomics Introduces PathogINDICAtor Assay Roche Introduces cobas DPX Test 8. RECENT INDUSTRY ACTIVITY Abbott Files for Cancellation of Acquisition Agreement with Alere Hologic Obtains CE Mark Approval for Aptima HSV Assay Hologic Obtains Health Canada Approval for Aptima Hepatitis C and B Quant Assays Quidel Obtains FDA Approval for Solana Assay for Various Streptococcus Strains Quidel Obtains FDA Approval for Solana Assay for Influenza A&B BD Receives FDA Approval for BD MAX CT/GC/TV Assay OraSure Obtains BARDA Funding for Zika Tests Alere Obtains FDA Approval for Alere i RSV Rapid Molecular Test Magellan Diagnostics Obtains Chinese Approval for LeadCare II Alere Receives CE Mark for Alere Reader Sekisui Secures Distribution Rights for FastPack IP System from Qualigen bioMrieux Submits 510(k) Application for BacT/ALERT VIRTUO Alere Begins Operations at New Facility in India Alere Obtains WHO Prequalification for Alere HIV Combo Hologic and Grifols Receive FDA Approval for Procleix Zika Virus Assay Meridian Obtains FDA Approval for illumigene Mycoplasma Direct Assay Alere Announces WHO Prequalification for Alere q HIV-1/2 Detect Assay BD and Check-Points Enter into Development and Distribution Agreement Luminex to Acquire Nanosphere bioMrieux Takes Over Hyglos BD Receives CE Mark for BD MAX Vaginal Panel Siemens Healthcare Changes Name to Siemens Healthineers Sekisui and Qualigen Enter into Partnership Meridian Obtains CE Mark for illumigene Mycoplasma Direct BioFire Obtains FDA and CE Mark Approval for FilmArray Torch use with all FilmArray Panels Roche Receives FDA IND Approval for cobas Zika Assay Meridian Takes Over Magellan Biosciences Thermo Fisher Obtains FDA Approval for B - R - A - H - M - S PCT Assay for Sepsis Risk Assessment BioFire Obtains FDA Approval for FilmArray Torch for use with FilmArray Respiratory Panel Abbott Signs Acquisition Agreement with Alere Siemens Receives FDA Approval for Sysmex CS-2100i System Bio-Rad Receives FDA Approval for TANGO infinity system Bio-Rad Obtains FDA Approval for D-100 System for A1c Testing MedMira Obtains FDA Approval for Reveal G4 Rapid HIV-1 Antibody Test FDA Approves cobas HBV and cobas HCV Viral Load Tests for cobas 6800 and cobas 8800 Systems Hologic Obtains CE-IVD Certification for Aptima HCV Quant Dx Assay on Panther System BD and Seegene Enter into Collaboration Agreement FDA Emergency Authorization for OraSure OraQuick Ebola Rapid Antigen Test Bio-Rad Obtains Pre-Market Approval for BioPlex 2200 HIV Ag-Ab Assay FDA Approves VIDAS 3 Immunoassay from bioMrieux Meridian Obtains FDA Approval for illumigene HSV 1&2 Charles River Laboratories Acquires Celsis International FDA Approves Quidel Solana Molecular System and Solana Molecular Assay FDA Approves Roche cobas HSV 1 and 2 Test FDA Approves Roche cobas Cdiff Test MedMira Submits Supplement for FDA Approval of Reveal G4 Rapid HIV-1 Antibody Test FDA Approves Alere i Strep A Rapid Molecular Test bioMrieux Acquires CREERAM Tools FDA Gives CLIA Waiver Alere i Influenza A & B Test Alere Obtains CE Mark Approval for Alere HIV Combo Alere Obtains IVD CE Mark Approval for Alere q HIV-1/2 Detect Assay for Molecular Diagnosis of HIV at the Point of Care FDA Gives CLIA Waiver for Alere i Strep A Rapid Molecular Test BioFire Obtains FDA Approval and CE-IVD Marking for FilmArray 2.0 System FDA Approves Next Generation cobas MRSA/SA Test of Roche FDA Approves cobas TaqScreen MPX Test, v2.0 of Roche bioMrieux Signs Strategic Agreement with COPAN 9. FOCUS ON SELECT GLOBAL PLAYERS Abbott Laboratories (US) Abbott Molecular, Inc. (US) Alere Inc. (US) Beckman Coulter, Inc. (US) Becton Dickinson and Company (US) bioMrieux SA (France) bioMerieux, Inc. (US) Bio-Rad Laboratories, Inc (US) Cellabs Pty Ltd (Australia) Cepheid Inc. (US) CorisBioconcept SPRL (Belgium) F. Hoffmann-La Roche AG (Switzerland) Hologic, Inc. (US) MedMira Inc. (Canada) Meridian Bioscience, Inc. (US) OraSure Technologies, Inc. (US) Orion Diagnostica Oy (Finland) QIAGEN N.V. (The Netherlands) Quidel Corporation (US) Sekisui Diagnostics, LLC (US) Siemens Healthcare GmbH (Germany) Thermo Fisher Scientific Inc. (US) Oxoid Limited (UK) 10. GLOBAL MARKET PERSPECTIVE Total Companies Profiled: 83 (including Divisions/Subsidiaries -90)

  • The United States (55)
  • Canada (1)
  • Japan (4)
  • Europe (27)
    • France (3)
    • Germany (9)
    • The United Kingdom (3)
    • Italy (2)
    • Spain (1)
    • Rest of Europe (9)
  • Asia-Pacific (Excluding Japan) (2)
  • Middle East (1)

For more information about this report visit https://www.researchandmarkets.com/research/p...mated?w=12

CONTACT: ResearchAndMarkets.com Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 Related Topics: Biotechnology